多发性硬化女性妊娠期治疗管理与复发风险
这项多中心回顾性队列研究基于法国MS注册数据库1990-2023年数据,纳入6341例次妊娠,评估妊娠期疾病修饰治疗(DMT)管理对复发率的影响。妊娠期DMT管理显著增加妊娠期和产后年化复发率(ARR),尤其是妊娠前使用那他珠单抗并长时间中断或使用芬戈莫德者;妊娠前使用抗CD20策略效果最佳。
要点
- 妊娠期DMT管理使妊娠期ARR升高(cRR 1.13),产后ARR升高(cRR 1.08)。
- 妊娠前使用那他珠单抗并长时间中断者复发风险最高(cRR 2.18),芬戈莫德者次之(cRR 2.15)。
- 抗CD20策略较DMT中断显著降低复发风险(cRR 0.38)。
核心结论
- 妊娠期DMT管理显著增加MS复发风险,尤其在妊娠前使用那他珠单抗并长时间中断或使用芬戈莫德的患者中。
- 妊娠前使用抗CD20策略是减轻该风险最有效的治疗策略。
主要发现
- 妊娠期DMT管理显著增加妊娠期ARR(cRR 1.13;95% CI 1.06-1.22)和产后ARR(cRR 1.08;95% CI 1.01-1.16)。
- 妊娠前使用那他珠单抗并长时间中断者cRR为2.18(95% CI 1.76-2.69),使用芬戈莫德者cRR为2.15(95% CI 1.60-2.93)。
- 与DMT中断相比,抗CD20策略cRR为0.38(95% CI 0.25-0.52),那他珠单抗短中断策略cRR为0.80(95% CI 0.71-0.90)。
- 干扰素β策略cRR为0.93(95% CI 0.86-0.99),醋酸格拉替雷策略cRR为0.91(95% CI 0.84-0.99)。
关键数值与推荐
- 妊娠期DMT管理对妊娠期ARR的cRR为1.13(95% CI 1.06-1.22),对产后ARR的cRR为1.08(95% CI 1.01-1.16)。
- 抗CD20策略较DMT中断的cRR为0.38(95% CI 0.25-0.52)。
- 那他珠单抗短中断策略cRR为0.80(95% CI 0.71-0.90)。
- 干扰素β策略cRR为0.93(95% CI 0.86-0.99),醋酸格拉替雷策略cRR为0.91(95% CI 0.84-0.99)。
临床怎么用
- 对计划妊娠的MS患者,应优先考虑妊娠前使用抗CD20策略以降低妊娠期和产后复发风险。
- 应避免妊娠前使用那他珠单抗后长时间中断或使用芬戈莫德,因其与较高的复发风险相关。
局限性
- 本研究为回顾性队列研究,可能存在残余混杂。
- 数据来源于法国MS注册数据库,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In women with multiple sclerosis (MS), disease-modifying therapy (DMT) management during pregnancy might impact relapse risk. OBJECTIVE: To estimate the effect of DMT management during pregnancy on MS relapse rate and compare different therapeutic strategies. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter retrospective cohort study using data from January 1990 to December 2023. Data were extracted in December 2023 from the French MS registry. Among 52 955 women in the registry, we included pregnancies identified through childbirths in patients with relapsing-onset MS who were monitored for at least 18 months before delivery and 9 months after. Pregnancies occurring less than 18 months apart or with missing month of birth were excluded. EXPOSURES: Mediation analysis was used to estimate the total, direct, and indirect (mediated by DMT management) effects of pregnancy. Different therapeutic strategies were compared: DMT interruption, switching to or maintaining interferon β or glatiramer acetate, switching to or maintaining natalizumab until the third trimester, and switching to or maintaining intravenous anti-CD20 and interrupting it 3 months before conception. MAIN OUTCOMES AND MEASURES: The primary outcome was the annualized relapse rate (ARR) during the preconception, gestation, and postpartum periods. Within a causal inference framework, counterfactual ARRs were estimated using longitudinal g-computation, combining a random forest algorithm for predicting DMTs, and a mixed-effects Poisson model for relapses. RESULTS: We included 6341 pregnancies occurring in 4998 women (mean [SD] age at conception, 31.5 [4.5] years). DMT management during pregnancy significantly increased ARR during gestation (causal rate ratio [cRR], 1.13; 95% CI, 1.06-1.22) and postpartum (cRR, 1.08; 95% CI, 1.01-1.16) periods. This led to a deleterious total effect of pregnancy on ARR, particularly in women receiving natalizumab before pregnancy with prolonged interruption (ie, interruption before the second trimester or resumption more than 3 months after delivery; cRR, 2.18; 95% CI, 1.76-2.69), and in women receiving fingolimod (cRR, 2.15; 95% CI, 1.60-2.93). Compared to DMT interruption, anti-CD20 strategy was the most effective (cRR, 0.38; 95% CI, 0.25-0.52), followed by the natalizumab strategy with short interruption (cRR, 0.80; 95% CI, 0.71-0.90), whereas interferon β (cRR, 0.93; 95% CI, 0.86-0.99) and glatiramer acetate strategies (cRR, 0.91; 95% CI, 0.84-0.99) were less effective. CONCLUSION: In this study, DMT management during pregnancy significantly increased relapse risk, particularly in patients receiving natalizumab with prolonged interruption or fingolimod. The strategy based on the use of anti-CD20 before pregnancy was the most effective to mitigate this risk.
引用
- Gavoille A, Rollot F, Casey R, et al. Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis. JAMA Neurol. 2025. PMID: 40758347. doi:10.1001/jamaneurol.2025.2550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。